European biotech is a hot topic among investors. They have supported as many start-ups as in the US but have seen far from equivalent returns. So what's going on? Science|Business talks to biotechnology consultant John Hodgson.
The lack of funding from the private sector is still holding back the development of the European biotech sector vis a vis the US despite a similar number of companies in each.
OncoMethylome Sciences is planning to raise funds via an IPO. Its diagnostics can detect early-stage cancer and predict the response to particular cancer drugs.
Manchester Metropolitan University has recruited academic and industrial partners to a £5 million programme that will assess the problems confronting the global airline industry and help to develop solutions.
French and Belgian researchers have genetically modified strains of the bacteria as treatments for human gastrointestinal disorderse – and are keen to form licensing and partnering deals to take this research forward.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.